Intersect ENT
1555 Adams Drive
Menlo Park
California
94025
United States
Tel: 650-641-2100
Website: https://www.intersectent.com/
Email: info@intersectent.com
169 articles about Intersect ENT
-
Intersect ENT Announces Preliminary Revenue for Fourth Quarter of 2020
1/12/2021
Preliminary Unaudited Fourth Quarter 2020 Revenue Expected to be $27.7 to $28.1 Million
-
Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference
12/17/2020
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that management will participate in the 39th Annual J.P. Morgan Healthcare Conference.
-
Intersect ENT to Participate at Upcoming Investor Conferences - Nov 05, 2020
11/5/2020
Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, announced that management will participate in the following upcoming investor conferences:
-
Intersect ENT Reports Third Quarter 2020 Financial Results
11/2/2020
Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, reported financial results for the third quarter ended September 30, 2020.
-
Intersect ENT Announces Preliminary Revenue for Third Quarter of 2020
10/15/2020
Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, announced preliminary third quarter 2020 revenue and provided a business update.
-
Intersect ENT to Report Third Quarter 2020 Financial Results
10/9/2020
Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it will release third quarter 2020 financial results on November 2, 2020.
-
Intersect ENT Closes Acquisition of Fiagon AG Medical Technologies
10/2/2020
Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced it closed the previously announced transaction to acquire Fiagon AG Medical Technologies , a leader in electromagnetic surgical navigation solutions, for €60 million in cash. Under the previously disclosed terms of the agreement, as announced on September 15, 20
-
Intersect ENT Announces Agreement to Acquire Fiagon AG Medical Technologies for €60 Million Paid Over Three Years
9/15/2020
Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced it has entered into an agreement to acquire Fiagon AG Medical Technologies, a leader in electromagnetic surgical navigation solutions, for €60 million in cash
-
Intersect ENT Announces Specialty Pharmacy Partnership Agreement with AllianceRx Walgreens Prime to Distribute SINUVA® Sinus Implant
9/10/2020
Agreement expands patient access to SINUVA treatment with announcement of third partnership with a specialty pharmacy
-
Intersect ENT Reports Second Quarter 2020 Financial Results
8/4/2020
Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, reported financial results for the second quarter ended June 30, 2020.
-
Intersect ENT to Report Second Quarter 2020 Financial Results
7/22/2020
Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it will release second quarter 2020 financial results on August 4, 2020.
-
Intersect ENT Announces Independent Analysis in UK Confirming Cost Effectiveness of PROPEL® Steroid Releasing Sinus Implant Following Sinus Surgery for Chronic Sinusitis
6/23/2020
Intersect ENT, Inc. announced the results of a United Kingdom-based independent analysis measuring costs and patient outcomes of the PROPEL steroid releasing sinus implant compared to a non-drug-eluting spacer following endoscopic sinus surgery for patients with chronic sinusitis.
-
CMS Approves SINUVA® Sinus Implant for Reimbursement with New C-Code and Pass-Through Payment Status
6/9/2020
Intersect ENT®, Inc. (Nasdaq: XENT), , today announced that the Centers for Medicare and Medicaid Services (CMS) has approved SINUVA® (mometasone furoate) Sinus Implant for transitional pass-through payment status for reimbursement under the Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgery Center Payment System
-
Intersect ENT to Present at the William Blair 40th Annual Growth Stock Conference
5/26/2020
Intersect ENT, Inc., announced that management will participate in a virtual fireside chat at the William Blair 40th Annual Growth Stock Conference.
-
Intersect ENT Announces $65 Million Convertible Notes Investment from Deerfield Management
5/11/2020
Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, announced that it has closed a $65 million convertible notes financing with a fund managed by Deerfield Management Company L.P.
-
Intersect ENT Reschedules Time of First Quarter 2020 Financial Results Conference Call to 4:30 P.M. ET on May 11, 2020
5/8/2020
Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced the Company has rescheduled a conference call to discuss its first quarter 2020 financial results to 4:30 p.m. ET on Monday, May 11, 2020. To access the conference call via the internet, go to the "Investor Relations" page of the company's website at www.intersectENT.com . To a
-
Intersect ENT to Present at the 2020 Bank of America Merrill Lynch Global Healthcare Conference
5/7/2020
Intersect ENT, Inc., announced that management will participate in a virtual fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference.
-
Intersect ENT to Report First Quarter 2020 Financial Results
4/28/2020
Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, announced that it will release first quarter 2020 financial results on May 11, 2020.
-
Intersect ENT Announces Preliminary Revenue for First Quarter 2020 and Provides Business Update in Response to COVID-19 Pandemic
4/13/2020
Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced preliminary first quarter 2020 revenue and provided a business update on its actions in response to the coronavirus (COVID-19) pandemic.
-
Intersect ENT Reports Fourth Quarter and Full Year 2019 Results
2/24/2020
Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, reported financial results for the fourth quarter and full year ended December 31, 2019.